Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Omeros Co. (NASDAQ:OMER) have been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $22.50.

Several equities research analysts have recently weighed in on OMER shares. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Tuesday.

Omeros Trading Down 3.8 %

NASDAQ:OMER opened at $7.91 on Wednesday. The firm’s fifty day simple moving average is $8.64 and its 200 day simple moving average is $7.61. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60. The firm has a market capitalization of $458.38 million, a price-to-earnings ratio of -3.42 and a beta of 2.03.

Hedge Funds Weigh In On Omeros

Several large investors have recently modified their holdings of the stock. Truvestments Capital LLC raised its stake in Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP acquired a new position in Omeros in the fourth quarter worth $46,000. Picton Mahoney Asset Management increased its stake in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 4,404 shares during the last quarter. Finally, US Bancorp DE acquired a new stake in shares of Omeros during the fourth quarter worth $81,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.